Page 65 - MemoriaSAM-Eng

www.cibersam.es

• A F. Serotonin receptors involved in antidepressant effects.Pharmacol Ther.
Most relevant rTigAS
2013 Jan;137(1):119-31.
scientific
• SAnTAnA n, Mengod g, ArTigAS F. Expression of α(1)-adrenergic receptors in rat prefron-
articles
tal cortex: cellular co-localization with 5-HT(2A) receptors.Int J Neuropsychophar-
macol. 2013 Jun;16(5):1139-51.

• CelAdA P, llAdó-PelForT l, SAnTAnA n, KArgieMAn l, TroyAno-rodriguez e, rigA MS eT Al..

Disruption of thalamocortical activity in schizophrenia models: relevance to antipsy-
chotic drug action.Int J Neuropsychopharmacol. 2013 Nov;16(10):2145-63.

• C P, B A, A F. Serotonin 5-HT1A receptors as targets for agents
elAdAorTolozzirTigAS
to treat psychiatric disorders: rationale and current status of research.CNS Drugs.
2013 Sep;27(9):703-16.

• F-C A, S n, C A, C r, C MC, T M .. Acute 5-HT(1A)
erréSoyAnTAnAASTAñéorTéSArMonAoTheT Al
autoreceptor knockdown increases antidepressant responses and serotonin release
in stressful conditions.Psychopharmacology (Berl). 2013 Jan;225(1):61-74.

Highlights
The group has led a total of 12 grants during 2013, including 1 EU grant (IMI-
NEWMEDS, Grant 115008 ), 5 Spanish competitive grants (SAF2012-35183,

IPT-2012-1208-300000, PI10/01103, PI10/00290, PI12/00156), 1 international

grant (NARSAD Grant 20003) and 5 contracts with companies . Four new grants
have been awarded in 2013: 2 ISCIII (PI13/00038, PI13/01390), 1 international

grant (MJFF, Grant 9238) and 1 private contract. Two new patents have been

requested, one in Europe (PCT/EP2013/07241) and U.S. (14,065,024), and a
second one only in Europe (EP12382413.8).

From the studies carried out during 2013, we would highlight a) the development

of novel antidepressant strategies using RNAi, b) the study of the antidepressant
properties of deep brain stimulation, c) preclinical models of schizophrenia, and

d) identification of thalamocortical circuits as therapeutic targets in schizophre-

nia. The group’s activity has resulted in a total of 15 papers (8 original articles,
6 reviews, 1 editorial) of which 13 are in 1st quartile and 7 in 1st decile, with 6

national and 7 international collaborations.

Overall, these results keep a solid reputation of the group in the field of Neu-
ropsychopharmacology , as shown by its high level of citations (h-index of PI =

53), the involvement in several scientific societies (eg the PI was Chairman of the

Scientific Committee of the Spanish Society for Neuroscience in 2012-2013, and
has recently been elected councillor of CINP). Among the awards received during

2013, the PI gave one of the plenary lectures at the 26th ECNP Congress and one

of the group posters received the Poster Award. The PI was also invited to write a
paper on new trends in antidepressant treatments for a special issue of Eur Neu-

ropsychopharmaclogy to celebrate the ECNP 25th anniversary.
13
0
2
RT
PO
E
R
AL
U
NN
A
/
M
SA
ER
B
CI

65